Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Long noncoding RNA CMPK2 promotes colorectal cancer progression by activating the FUBP3–c-Myc axis

Oncogene volume 39, pages 3926–3938 (2020)Cite this article

Subjects

Abstract

Long noncoding RNAs (lncRNAs) have been shown to play crucial roles in cancer long noncoding RNAs (lncRNAs) have been known to play crucial roles in cancer development and progression by regulating chromatin dynamics and gene expression. However, only a few lncRNAs with annotated functions in the progression of colorectal cancer (CRC) have been identified to date. In the present study, the expression of lncCMPK2 was upregulated in CRC tissues and positively correlated with clinical stages and lymphatic metastasis. The overexpression of lncCMPK2 promoted the proliferation and cell cycle transition of CRC cells. Conversely, the silencing of lncCMPK2 restricted cell proliferation both in vitro and in vivo. lncCMPK2 was localized to the nucleus of CRC cells, bound to far upstream element binding protein 3 (FUBP3), and guided FUBP3 to the far upstream element (FUSE) of the c-Myc gene to activate transcription. lncCMPK2 also stabilized FUBP3. These results provide novel insights into the functional mechanism of lncCMPK2 in CRC progression and highlight its potential as a biomarker of advanced CRC and therapeutic target.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: LncCMPK2 is overexpressed in CRC tissues and cells.
Fig. 2: Overexpression of lncCMPK2 promotes CRC cells proliferation.
Fig. 3: Silencing of lncCMPK2 inhibits the proliferation of CRC.
Fig. 4: LncCMPK2 increases the stability of FUBP3 through interaction.
Fig. 5: LncCMPK2 increases the c-Myc expression via FUBP3 and promote CRC cell proliferation.
Fig. 6: The positive correlation among lncCMPK2, FUBP3, and c-Myc expression in CRC tissues.

Similar content being viewed by others

Data availability

Data and material are available in Supplementary Data.

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.

    Article  Google Scholar 

  2. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–91.

    Article  Google Scholar 

  3. Naxerova K, Reiter JG, Brachtel E, Lennerz JK, van de Wetering M, Rowan A, et al. Origins of lymphatic and distant metastases in human colorectal cancer. Science. 2017;357:55–60.

    Article  CAS  Google Scholar 

  4. Bhan A, Mandal SS. Long noncoding RNAs: emerging stars in gene regulation, epigenetics and human disease. ChemMedChem. 2014;9:1932–56.

    Article  CAS  Google Scholar 

  5. Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172:393–407.

    Article  CAS  Google Scholar 

  6. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov. 2011;1:391–407.

    Article  CAS  Google Scholar 

  7. Hajjari M, Salavaty A. HOTAIR: an oncogenic long non-coding RNA in different cancers. Cancer Biol Med. 2015;12:1–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Liu J, Peng WX, Mo YY, Luo D. MALAT1-mediated tumorigenesis. Front Biosci (Landmark Ed). 2017;22:66–80.

    Article  CAS  Google Scholar 

  9. Silva JM, Boczek NJ, Berres MW, Ma X, Smith DI. LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation. RNA Biol. 2011;8:496–505.

    Article  CAS  Google Scholar 

  10. Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013;23:1446–61.

    Article  CAS  Google Scholar 

  11. Arab K, Park YJ, Lindroth AM, Schafer A, Oakes C, Weichenhan D, et al. Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A. Mol Cell. 2014;55:604–14.

    Article  CAS  Google Scholar 

  12. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, et al. lncRNA epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that Interacts with MYC and promotes cell-cycle progression in cancer. Cancer Cell. 2018;33:706–20.e709.

    Article  CAS  Google Scholar 

  13. Gu J, Wang Y, Wang X, Zhou D, Wang X, Zhou M, et al. Effect of the LncRNA GAS5-MiR-23a-ATG3 axis in regulating autophagy in patients with breast cancer. Cell Physiol Biochem. 2018;48:194–207.

  14. Malakar P, Stein I, Saragovi A, Winkler R, Stern-Ginossar N, Berger M, et al. Long noncoding RNA MALAT1 regulates cancer glucose metabolism by enhancing mTOR-mediated translation of TCF7L2. Cancer Res. 2019;79:2480–93.

  15. Liu T, Han Z, Li H, Zhu Y, Sun Z, Zhu A. LncRNA DLEU1 contributes to colorectal cancer progression via activation of KPNA3. Mol Cancer. 2018;17:118.

    Article  Google Scholar 

  16. Ren J, Ding L, Zhang D, Shi G, Xu Q, Shen S, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics. 2018;8:3932–48.

    Article  CAS  Google Scholar 

  17. Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013;23:1446–61.

    Article  CAS  Google Scholar 

  18. Ma Y, Yang Y, Wang F, Moyer MP, Wei Q, Zhang P, et al. Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/beta-catenin signalling pathway via suppression of activator protein 2alpha. Gut. 2016;65:1494–504.

    Article  CAS  Google Scholar 

  19. Han Q, Xu L, Lin W, Yao X, Jiang M, Zhou R, et al. Long noncoding RNA CRCMSL suppresses tumor invasive and metastasis in colorectal carcinoma through nucleocytoplasmic shuttling of HMGB2. Oncogene. 2019;38:3019–32.

    Article  CAS  Google Scholar 

  20. Avigan MI, Strober B, Levens D. A far upstream element stimulates c-myc expression in undifferentiated leukemia cells. J Biol Chem. 1990;265:18538–45.

    CAS  PubMed  Google Scholar 

  21. Zheng P, Yin Z, Wu Y, Xu Y, Luo Y, Zhang TC. LncRNA HOTAIR promotes cell migration and invasion by regulating MKL1 via inhibition miR206 expression in HeLa cells. Cell Commun Signal. 2018;16:5.

    Article  Google Scholar 

  22. Beckedorff FC, Ayupe AC, Crocci-Souza R, Amaral MS, Nakaya HI, Soltys DT, et al. The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation. PLoS Genet. 2013;9:e1003705.

  23. Chen Q, Cai J, Wang Q, Wang Y, Liu M, Yang J, et al. Long non-coding RNA NEAT1, regulated by the EGFR pathway, contributes to glioblastoma progression through the WNT/beta-Catenin pathway by scaffolding EZH2. Clin Cancer Res. 2018;24:684–95.

  24. Kambara H, Niazi F, Kostadinova L, Moonka DK, Siegel CT, Post AB, et al. Negative regulation of the interferon response by an interferon-induced long non-coding RNA. Nucleic Acids Res. 2014;42:10668–80.

    Article  CAS  Google Scholar 

  25. Mariotti B, Servaas NH, Rossato M, Tamassia N, Cassatella MA, Cossu M, et al. The long non-coding RNA NRIR drives IFN-response in monocytes: implication for systemic sclerosis. Front Immunol. 2019;10:100.

    Article  CAS  Google Scholar 

  26. Munschauer M, Nguyen CT, Sirokman K, Hartigan CR, Hogstrom L, Engreitz JM, et al. The NORAD lncRNA assembles a topoisomerase complex critical for genome stability. Nature. 2018;561:132–6.

  27. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142:409–19.

    Article  CAS  Google Scholar 

  28. Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet. 2011;43:621–9.

    Article  CAS  Google Scholar 

  29. Duncan R, Bazar L, Michelotti G, Tomonaga T, Krutzsch H, Avigan M, et al. A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev. 1994;8:465–80.

    Article  CAS  Google Scholar 

  30. Weber A, Kristiansen I, Johannsen M, Oelrich B, Scholmann K, Gunia S, et al. The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer. 2008;8:369.

    Article  Google Scholar 

  31. Zubaidah RM, Tan GS, Tan SB, Lim SG, Lin Q, Chung MC. 2-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis. Proteomics. 2008;8:5086–96.

    Article  CAS  Google Scholar 

  32. Davis-Smyth T, Duncan RC, Zheng T, Michelotti G, Levens D. The far upstream element-binding proteins comprise an ancient family of single-strand DNA-binding transactivators. J Biol Chem. 1996;271:31679–87.

    Article  CAS  Google Scholar 

  33. Dang CV. MYC on the path to cancer. Cell. 2012;149:22–35.

    Article  CAS  Google Scholar 

  34. Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16:253–64.

    Article  CAS  Google Scholar 

  35. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, et al. Genomic targets of the human c-Myc protein. Genes Dev. 2003;17:1115–29.

    Article  CAS  Google Scholar 

  36. Gonzalez V, Hurley LH. The c-MYC NHE III(1): function and regulation. Annu Rev Pharmacol Toxicol. 2010;50:111–29.

    Article  CAS  Google Scholar 

  37. Quinn LM. FUBP/KH domain proteins in transcription: back to the future. Transcription. 2017;8:185–92.

    Article  CAS  Google Scholar 

  38. Huang H-I, Chang Y-Y, Lin J-Y, Kuo R-L, Liu H-P, Shih S-R, et al. Interactome analysis of the EV71 5′ untranslated region in differentiated neuronal cells SH-SY5Y and regulatory role of FBP3 in viral replication. Proteomics. 2016;16:2351–62.

    Article  CAS  Google Scholar 

  39. Kortlever RM, Sodir NM, Wilson CH, Burkhart DL, Pellegrinet L, Brown Swigart L, et al. Myc cooperates with Ras by programming inflammation and immune suppression. Cell. 2017;171:1301–15.e1314.

    Article  CAS  Google Scholar 

  40. Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14:430–9.

    Article  CAS  Google Scholar 

  41. Zhao L, Wang H, Liu C, Liu Y, Wang X, Wang S, et al. Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1. Gut. 2010;59:1226–35.

    Article  CAS  Google Scholar 

  42. Wang H, Shi J, Luo Y, Liao Q, Niu Y, Zhang F, et al. LIM and SH3 protein 1 induces TGFbeta-mediated epithelial-mesenchymal transition in human colorectal cancer by regulating S100A4 expression. Clin Cancer Res. 2014;20:5835–47.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Editage [www.editage.cn] and BioMed Proofreading@ LLC [www.biomedproofreading.com] for English language editing.

Funding

This work was supported by the National Natural Science Foundation of China (nos. 81572813, 81773082, 81702903, and 81872423), Guangdong Natural Science Foundation (2016A030313626, 2017A030310038, 2018B030311036), and Fork Ying Tung Education Foundation (161035).

Author information

Author notes

  1. These authors contributed equally: Qingzu Gao, Rui Zhou

Authors and Affiliations

  1. Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China

    Qingzu Gao, Rui Zhou, Yuan Meng, Ling Wu, Rui Li, Fengliu Deng, Chuang Lin & Liang Zhao

  2. Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China

    Qingzu Gao

  3. Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China

    Qingzu Gao, Rui Zhou, Ling Wu, Rui Li, Fengliu Deng & Liang Zhao

  4. Department of Pathology, The Second People’s Hospital of Longgang District, Shenzhen, China

    Yuan Meng

  5. Department of Endocrinology, The First Affiliated Hospital of Xinxiang Medical University, Guangzhou, China

    Rongfei Duan

Authors
  1. Qingzu Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rui Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuan Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rongfei Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ling Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fengliu Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chuang Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Liang Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LZ led the study design and prepared the paper. Q-ZG and RZ carried out the experiments. YM and R-FD performed statistical analysis; LW and RL assisted in tissue sample collection. F-LD performed data analysis and interpretation. CL collected the data.

Corresponding author

Correspondence to Liang Zhao.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All experiments performed are endorsed by the Ethics Committee of Southern Medical University and complied with the Declaration of Helsinki. All animal experiments were carried out with the approval of the Southern Medical University Animal Care and Use Committee in accordance with the guidelines for the ethical treatment of animals. All animal experiments involved ethical and humane treatment under a license from the Guangdong Provincial Bureau of Science.

Informed consent

No informed consent was required because data were analyzed anonymously.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gao, Q., Zhou, R., Meng, Y. et al. Long noncoding RNA CMPK2 promotes colorectal cancer progression by activating the FUBP3–c-Myc axis. Oncogene 39, 3926–3938 (2020). https://doi.org/10.1038/s41388-020-1266-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-020-1266-8

This article is cited by

Search

Advanced search

Quick links